Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C

Autor: Eijiro Hayashi, Hirayuki Enomoto, Hiroyuki Ogawa, Toshikazu Hada, Hirokazu Uyama, Norio Hayashi, Yorihide Okuda, Kenya Yoshida, Mitsunari Yamamoto, Hideji Nakamura
Rok vydání: 2007
Předmět:
Zdroj: Hepatology Research. 37:325-330
ISSN: 1872-034X
1386-6346
Popis: Aims: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. In this study we investigated the efficacy of initial high-dose IFN with ribavirin and amantadine on the virological response in patients with chronic hepatitis C with a high viral load of genotype 1b. Methods: Twenty-two patients with high viral loads of genotype 1b hepatitis C virus were enrolled in this pilot study. Patients were administered IFN-beta for four weeks and then IFN-alpha2b for 22 weeks with daily oral administration of ribavirin and amantadine. Results: A sustained virological response (SVR) was shown in 31.8% (seven of 22 patients). With the naive patients, the SVR rate was 21.4% (three of 14 patients). In patients who could not eradicate HCV-RNA by previous IFN monotherapy, the SVR rate was 50% (four of eight patients). Conclusion: Triple therapy with an initial high dose of IFN with ribavirin and amantadine may be effective, especially for chronic hepatitis C IFN-retreatment patients with a high viral load of genotype 1b.
Databáze: OpenAIRE